

■ Accreditation

Mount Sinai Medical Center is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor continuing medical education for physicians. Mount Sinai designates this educational activity for a maximum of 11 AMA PRA Category 1 Credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.

■ Psychology Credit

The Symposium on Early Alzheimer's Disease has been approved by the Florida Board of Psychology and the Miami Area Geriatric Education Center (MAGEC). This program has been approved for 11 contact hours. (MAGEC CE Broker Tracking #20-252935).

■ Disclosure Statement

Faculty relationship(s) with industry will be disclosed and available in the Symposium Syllabus and at the meeting site. In addition, disclosure to the audience will be made by the Faculty prior to their presentations.

Mount Sinai Medical Center in accordance with the Standards for Commercial Support of the Accreditation Council for Continuing Medical Education (ACCME) will disclose the existence of any significant financial interest or other relationship that a faculty member/spouse or partner has (1) with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services and (2) with any commercial supporters of the activity. Faculty is also required to disclose to the audience, during their presentation, any investigational/unlabeled use that is discussed. The intent of this disclosure is not to prevent a speaker with a significant financial or other relationship from making a presentation, but rather to provide the attendees with information on which they can make their own judgments.

■ Symposium Information

Please contact one of the following:

Warren Barker

Wien Center for Alzheimer's Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2592 Fax: 305-674-2996

E-mail: info@mcisymposium.org

Web: www.mcisymposium.org

Yirah Ochoa

Wien Center for Alzheimer's Disease
& Memory Disorders
Mount Sinai Medical Center
Phone: 305-674-2259
Email: mcisymposium@msmc.com

Mount Sinai
MEDICAL CENTER

Wien Center
4300 Alton Road
Miami Beach, FL 33140

**8TH ANNUAL
MCI
SYMPOSIUM**

**March 12 - 13
2010**

Save the Date!

For information please visit:

www.mcisymposium.org

or

Email: info@mcisymposium.org

www.mcisymposium.org

MARK YOUR CALENDAR

8TH ANNUAL

Symposium on
Early Alzheimer's
Disease

Mount Sinai
MEDICAL CENTER

MILD COGNITIVE IMPAIRMENT (MCI) SYMPOSIUM

Theme for 2010: Focus on Early and Preclinical Alzheimers Disease

Presented By:

Mount Sinai Medical Center, Miami Beach, Florida

FRIDAY – SATURDAY March 12 - 13, 2010

Symposium Location:

Eden Roc Hotel

4525 Collins Avenue
Miami Beach, FL 33140

Program Director:

Ranjan Dua, MD

Medical Director, Wien Center for Alzheimer's Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach, FL



■ Needs Assessment

Unless ways are found to prevent Alzheimer’s Disease (AD) or delay its onset, it is projected that 13 million people in the United States will have AD by 2050. Individuals with AD suffer from cognitive and functional impairment, loss of productivity and significant deterioration in over-all quality of life. Most will develop problematic behaviors and many will need long-term care. In addition, caregivers of the patients are often affected by physical burden, emotional distress and financial hardship.

Since the development of criteria for AD almost twenty-five years ago, there have been major advances in our understanding of the biology and early clinical features of AD and other causes of dementia. This has led to improvements in clinical assessment and brain imaging, which has enabled clinicians to diagnose AD more reliably and at an earlier stage of illness. Patients classified as having a pre-dementia condition known as Mild Cognitive Impairment (MCI) are at increased risk for progressing to AD or dementia. Thus, American Academy of Neurology Practice Guidelines recommend that clinicians identify and monitor MCI using cognitive test batteries. The early diagnosis of dementing illnesses can lead to beneficial pharmacological treatment and non-pharmacological interventions (e.g., caregiver education, legal and financial counseling).

However, several studies have shown that physicians often lack knowledge of the early signs and symptoms of AD resulting in a delay in diagnosis and intervention. Many physicians are also unaware of the advantages and limitations of new assessment tools, or how to interpret their results in clinical practice. Clinicians also need information about the latest AD research to respond to patient questions and to refer to clinical trials.

■ Target Audience

- This activity is designed for:
- Neurologists
 - Psychiatrists
 - Geriatricians & Gerontologists
 - Epidemiologists
 - Neuropsychologists
 - Psychologists
 - Neuroscientists

■ Educational Objectives

The purpose of this symposium is to provide a forum for new information and for in-depth discussions about advances in research, related to the clinical diagnosis, progression and treatment of Alzheimer’s Disease. This symposium will emphasize the early stage of AD and the preclinical deficits that are associated with increased risk for subsequent dementia.

We will examine recent developments in understanding risk factors which lay the groundwork for potential strategies for treating and delaying Alzheimer’s disease. We will present results from several longitudinal and cross-sectional studies that have explored clinical, imaging and biomarkers factors that are related to AD.

The symposium will include two keynote addresses and four individually themed symposia, each featuring national experts in the fields of neurology, psychiatry, geriatrics, neuropsychology, radiology, epidemiology, genetics and pharmacology. Each mini-symposium will be followed by an extended discussion period, allowing active audience participation to promote a better understanding of the issues.

Upon completion of this symposium, the attendees should be able to:

- Describe the rationale for a preclinical AD diagnosis.
- Name preclinical factors that increase the risk for subsequent AD or dementia.
- Discuss the results of clinical drug studies and strategies to enrich prevention trials.
- Recognize the difference and similarities between amnesic and non-amnesic MCI.
- Understand the challenges in interpreting the results of psychometric tests in MCI and early AD.



■ Distinguished Faculty

Program Director

Ranjan Duara, MD

Medical Director, Wien Center for Alzheimer’s Disease and Memory Disorders
Mount Sinai Medical Center, Miami Beach
Departments of Medicine, Neurology and Psychiatry
Miller School of Medicine, University of Miami, Miami, FL
Department of Neurology, University of South Florida College of Medicine, Tampa, FL

Keynote Speakers:

Mark W. Bondi, Ph.D., ABPP/CN

Professor of Psychiatry
VA San Diego Healthcare System
University of California
San Diego, California

John Morris, MD

Friedman Distinguished Professor of
Neurology
Washington University School of Medicine
St. Louis, Missouri

Distinguished Faculty:

Rhoda Au, PhD

Associate Professor of Neurology
Boston University School of Medicine
Boston, Massachusetts

Richard J. Caselli, MD

Professor and Chair, Department of
Neurology
Clinical Core Director, Arizona Alzheimer's
Disease Center
Mayo Clinic Arizona
Scottsdale, Arizona

Katherine (Nutter-Upham) Eskine, MA

PhD Candidate in the Cognition Brain and
Behavior Program
City University of New York
Brooklyn, New York

Norman L. Foster, M.D.

Professor of Neurology
Director, Center for Alzheimer’s Care,
Imaging and Research
Senior Investigator, The Brain Institute at The
University of Utah
Salt Lake City, Utah

Mary Ganguli, MD, MPH

Professor of Psychiatry and Epidemiology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Robert C. Green, MD, MPH

Professor of Neurology, Genetics, and
Epidemiology
Boston University School of Medicine
Director, Boston University Alzheimer’s
Disease Clinical and Research Program
Boston, Massachusetts

Amy Jak, Ph.D.

Assistant Professor of Psychiatry
University of California, San Diego, School
of Medicine
Director, TBI Cognitive Rehabilitation Clinic,
VA San Diego Healthcare System
San Diego, California

David Loewenstein PhD, ABPP/CN

Professor of Psychiatry and Behavioral
Sciences and Neurology,
University of Miami Miller School of
Medicine
Wien Center for Alzheimer’s Disease and
Memory Disorders, Mount Sinai
Miami, Florida

Jennifer J. Manly, PhD

Associate Professor of Neuropsychology
Taub Institute for Research on Alzheimer's
Disease and the Aging Brain
Columbia University Medical Center
New York City, New York

Lisa Mosconi, PhD

Assistant Professor of Psychiatry
PET Imaging Research Director, Center for
Brain Health
New York University School of Medicine
New York City, New York

Ronald Petersen, MD, PhD

Professor of Neurology and Alzheimer’s
Disease Research
Mayo Medical School
Rochester, Minnesota

Joseph Quinn, MD

Co-Director, Northwest Parkinson’s Disease
Research, Education and Clinical Centers
Associate Professor, Department of
Neurology
Oregon Health & Science University
Portland, Oregon

Catherine M. Roe, PhD

Research Instructor
Alzheimer's Disease Research Center
Washington University School of Medicine
St. Louis, Missouri

Eric Siemers, MD

Medical Director, Alzheimer's Disease Team
Lilly Corporate Center, Eli Lilly and Company
Indianapolis, Indiana

Reisa Sperling, M.D.

Associate Professor of Neurology, Harvard
Medical School
Director of Clinical Research, Memory
Disorders Unit
Brigham and Women's Hospital
Boston, Massachusetts



Friday, March 12, 2010

AM

- 7:00-8:00 Breakfast Buffet
- 8:00-8:15 Welcome and Introduction
Ranjan Duara MD
- 9:00 - 10:30 Mini-Symposium: PreClinical AD: Longitudinal Studies Chair:
Ronald Petersen, MD, PhD
- The preclinical phase of Alzheimer disease: A 20-year prospective study of the Framingham Cohort
Rhoda Au, PhD
- Longitudinal Cognitive Changes in PreMCI states: Effect of Clinical, Imaging and Genetic Factors
Richard Caselli, MD
- 2-4 year outcome of PreMCI states in the Florida ADRC
David Loewenstein, PhD
- 10:30 - 11:00 Open Discussion
- 11:00 - 11:15 Break
- 11:15 - 12:30 Mini-Symposium: Clinical Trials and Genetics of AD
Chair: Eric Siemers, MD
- Enriching Future Prevention Trials with Genetic Risk Assessment and Disclosure
Robert C. Green, MD, MPH
- Significance of the MIDAS and ADCS trials with DHA for Secondary Prevention and Treatment of AD
Joseph Quinn, MD
- The Future of Clinical Trials for Treatment and Prevention of AD
Eric Siemers, MD
- 12:30 - 1:15 Open Discussion

PM

- 1:15 - 2:30 Lunch Break
- 2:30 - 4:15 **Mini-Symposium:** Biomarkers for Early AD, MCI and PreMCI
Chair: TBD
- FDG-PET Imaging in the Evaluation of Very Early AD: Contributions of the Alzheimer's Disease Neuroimaging Initiative (ADNI)
Norman Foster, MD
- Amyloid Imaging and fMRI studies in Early AD
Reisa Sperling, MD
- Cerebral Glucose Metabolism in PreClinical AD with Maternal Family History of AD
Lisa Mosconi, PhD
- 4:15 - 5:00 Open Discussion

Saturday, March 13, 2010

AM

- 7:30 - 8:30 Breakfast Buffet
- 8:30 - 9:15 **Keynote Address:** Amnesic and Non-amnesic MCI are Distinct Entities – Fact or Fiction?
Mark Bondi, PhD
- 9:15 - 9:30 Break
- 9:30 - 11:30 Mini-Symposium: Challenges in Interpreting Psychometric Test Results in Early AD, MCI and PreMCI
Chair: Mary Ganguli, MD
- PreMCI, Alzheimer's Disease and Cognitive Reserve
Catherine Roe, PhD
- Verbal Fluency and Executive Function in MCI and Subjects with Cognitive Complaints
Katherine Nutter-Upham, MA
- Quantification of Neuropsychological Approaches to Defining MCI Subtypes
Amy Jak, PhD
- Assessment of Cognitive Impairment in Minority Population
Jennifer Manly, PhD
- 11:30 - 11:45 Break
- 11:45 - 12:30 Open Discussion
- 12:30 Adjourn



Registration Information

■ Method of Registration

To register by mail or fax:

please complete the registration form and send it with the payment to the above mailing address or fax number.

To register by email:

provide the information requested on the registration form in an e-mail message and send to: mcisymposium@msmc.com

To register by internet:

www.mcisymposium.org

Registration confirmations will be issued.

Payment:

Registration fees can be paid by credit card or check, no cash is accepted.

Please make all checks payable to:

MOUNT SINAI MEDICAL CENTER

Registration Fee Inclusions:

Registration fees include admittance to all the scientific conferences, conference materials, breakfast, lunch on the first day, refreshment breaks.

Registration Hours:


The conference registration desk will be staffed:

Thursday, March 11 4:00 pm – 7:00pm
Friday, March 12 7:00 am - 5:00 pm
Saturday, March 13 7:30 am - 12:30 pm

■ Symposium Location

Eden Roc Hotel:

4525 Collins Avenue, Miami Beach, Florida 33140
Phone: (800) 468-3571 or (305) 531-0000
Web-Site: www.marriott.com/miasr



The place to experience Miami Beach... On magnificently landscaped oceanfront grounds, the new Eden Roc brings dynamic design, unsurpassed luxury and cutting-edge technology together in one place – the place to be on Miami Beach. Following a \$200 million dollar renovation and expansion, the bold new Eden Roc, A Renaissance Beach

Resort and Spa, embraces its role as a timeless treasure, yet welcomes guests with a contemporary spirit. In this stunning locale, a pulsing nightlife, brilliant white-sand beaches, and sizzling culture combine for the perfect getaway. At the Eden Roc Hotel you will savor the best of this colorful city.

■ DRESS

Business casual attire is appropriate for all events. A light sweater or jacket is recommended in the meeting rooms.

■ Hotel Reservations

For the convenience of the 8th Annual Symposium on early Alzheimer's Disease attendees, a limited number of rooms have been reserved at the special daily rate of \$200 (single or double occupancy, plus resort fees, state and local taxes). To receive this conference rate, reservations must be made directly with the Eden Roc Hotel and you must mention that you are a registrant of the 8th Annual Symposium on Early Alzheimer's Disease. Rooms will be held at the special rate until Thursday, February 18, 2010. Rooms at the discounted rate will be allocated on a first-come, first-served basis. Reservations received after the cut-off date are subject to availability and prevailing rates.

Mount Sinai Medical Center is committed to making its CME activities accessible to all individuals. If you are in need of an accommodation, please do not hesitate to call and/or submit a description of your needs in writing within 5 weeks of the activity in order to receive service.

FOR ROOM RESERVATIONS CALL: (800) 468-3571 or (305) 531-0000
OR ACCESS THE HOTEL WEB SITE VIA www.marriott.com/miasr

MARK YOUR CALENDAR

8TH
ANNUAL

SYMPOSIUM ON EARLY ALZHEIMER'S DISEASE

■ THREE EASY WAYS TO REGISTER FOR THE EARLY ALZHEIMER'S DISEASE SYMPOSIUM 2010:

ONLINE:

www.mcisymposium.org

FAX:

Attn: Warren Barker
(305) 674-2996

MAIL:

Warren Barker
Wien Ctr
4300 Alton Road
Miami Beach, FL 33140

■ REGISTRANT INFORMATION Please print:

LAST NAME FIRST NAME MIDDLE NAME

DEGREE: ☐ MD ☐ DO ☐ PhD ☐ OTHER

INSTITUTION / ORGANIZATION

STREET ADDRESS

CITY STATE ZIP CODE COUNTRY

E-MAIL TELEPHONE

■ REGISTRATION FEES:

Physicians:

- ☐ \$340.00 (if dated/postmarked by February 21)
☐ \$390.00 (if dated/postmarked after February 21)
☐ \$440.00 (on site registration)

Non-Physicians:

- ☐ \$225.00 (if dated/postmarked by February 21)
☐ \$275.00 (if dated/postmarked after February 21)
☐ \$325.00 (on site registration)

Students:

- ☐ \$100.00

■ PAYMENT METHOD:

☐ American Express ☐ Master Card ☐ Visa ☐ Check in the amount of _____

Card No. _____ Expiration Date ____/____

Cardholder's Name _____

Signature _____

NAME & ADDRESS ON CARD IF DIFFERENT THAN ABOVE

Payment must accompany registration form. Refund Policy: Full refund will be given if written notice is received not later than February 21, 2010. All refunds will be processed after the meeting.